Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 3
1949 1
1950 2
1954 4
1955 4
1956 4
1957 3
1958 2
1959 1
1961 2
1962 3
1963 2
1964 4
1965 1
1966 1
1967 3
1968 3
1969 1
1970 3
1971 2
1972 2
1973 9
1974 12
1975 9
1976 4
1977 10
1978 7
1979 7
1980 7
1981 1
1982 5
1983 9
1984 14
1985 11
1986 11
1987 20
1988 35
1989 51
1990 41
1991 61
1992 62
1993 61
1994 63
1995 71
1996 94
1997 87
1998 90
1999 101
2000 98
2001 95
2002 90
2003 85
2004 109
2005 123
2006 100
2007 115
2008 104
2009 73
2010 78
2011 121
2012 108
2013 93
2014 108
2015 114
2016 118
2017 106
2018 104
2019 102
2020 110
2021 100
2022 109
2023 101
2024 56

Text availability

Article attribute

Article type

Publication date

Search Results

3,269 results

Results by year

Filters applied: . Clear all
Page 1
Dextromethorphan/Bupropion: First Approval.
Keam SJ. Keam SJ. CNS Drugs. 2022 Nov;36(11):1229-1238. doi: 10.1007/s40263-022-00968-4. CNS Drugs. 2022. PMID: 36301443 Review.
An oral, fixed-dose combination of dextromethorphan hydrobromide [an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist] and the antidepressant bupropion hydrochloride (an aminoketone and CYP2D6 inhibitor that increases dextrometh …
An oral, fixed-dose combination of dextromethorphan hydrobromide [an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist an …
Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI).
Iosifescu DV, Jones A, O'Gorman C, Streicher C, Feliz S, Fava M, Tabuteau H. Iosifescu DV, et al. J Clin Psychiatry. 2022 May 30;83(4):21m14345. doi: 10.4088/JCP.21m14345. J Clin Psychiatry. 2022. PMID: 35649167 Free article. Clinical Trial.
Results: A total of 327 patients were randomized: 163 patients to dextromethorphan-bupropion and 164 patients to placebo. Mean baseline MADRS total scores were 33.6 and 33.2 in the dextromethorphan-bupropion and placebo groups, respectively. ...Dextromethorphan …
Results: A total of 327 patients were randomized: 163 patients to dextromethorphan-bupropion and 164 patients to placebo. Mean baseli …
Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity.
Stahl SM. Stahl SM. CNS Spectr. 2019 Oct;24(5):461-466. doi: 10.1017/S1092852919001470. CNS Spectr. 2019. PMID: 31566163 Review.
The recent approval of the NMDA (N-methyl-d-aspartate) antagonist esketamine given intranasally for treatment-resistant depression has reinforced the need for agents with rapid onset with alternate mechanisms of action. Dextromethorphan/bupropion, an investigational medici …
The recent approval of the NMDA (N-methyl-d-aspartate) antagonist esketamine given intranasally for treatment-resistant depression has reinf …
Classics in Chemical Neuroscience: Dextromethorphan (DXM).
McClure EW, Daniels RN. McClure EW, et al. ACS Chem Neurosci. 2023 Jun 21;14(12):2256-2270. doi: 10.1021/acschemneuro.3c00088. Epub 2023 Jun 8. ACS Chem Neurosci. 2023. PMID: 37290117 Review.
Dextromethorphan (DXM) was introduced in 1958 as the first non-opioid cough suppressant and is indicated for multiple psychiatric disorders. ...
Dextromethorphan (DXM) was introduced in 1958 as the first non-opioid cough suppressant and is indicated for multiple psychiatric dis …
Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials.
Majeed A, Xiong J, Teopiz KM, Ng J, Ho R, Rosenblat JD, Phan L, Cao B, McIntyre RS. Majeed A, et al. Expert Opin Emerg Drugs. 2021 Mar;26(1):63-74. doi: 10.1080/14728214.2021.1898588. Epub 2021 Mar 12. Expert Opin Emerg Drugs. 2021. PMID: 33682569
AREAS COVERED: The synthesis herein of preclinical and clinical studies indicates that dextromethorphan (DXM) is well tolerated and exhibits clinically significant antidepressant effects; DXM combined with bupropion has demonstrated replicated and relatively rapid onset ef …
AREAS COVERED: The synthesis herein of preclinical and clinical studies indicates that dextromethorphan (DXM) is well tolerated and e …
Dextromethorphan abuse.
Boyer EW. Boyer EW. Pediatr Emerg Care. 2004 Dec;20(12):858-63. doi: 10.1097/01.pec.0000148039.14588.d0. Pediatr Emerg Care. 2004. PMID: 15572980 Review.
Dextromethorphan is an over-the-counter dissociative agent of increasing popularity as a drug of abuse among younger adolescents. ...Most cases improve with supportive care alone, but severely intoxicated patients may require significant attention. Because dextromethorp …
Dextromethorphan is an over-the-counter dissociative agent of increasing popularity as a drug of abuse among younger adolescents. ... …
Combinations of dextromethorphan for the treatment of mood disorders - a review of the evidence.
Parincu Z, Iosifescu DV. Parincu Z, et al. Expert Rev Neurother. 2023 Mar;23(3):205-212. doi: 10.1080/14737175.2023.2192402. Epub 2023 Mar 21. Expert Rev Neurother. 2023. PMID: 36943010 Review.
However, dextromethorphan studies in adults with TRD or with bipolar depression have shown mixed results. ...Additional studies analyzing the effects of dextromethorphan and bupropion for TRD and bipolar depression are needed....
However, dextromethorphan studies in adults with TRD or with bipolar depression have shown mixed results. ...Additional studies analy …
Dextromethorphan/quinidine: in pseudobulbar affect.
Garnock-Jones KP. Garnock-Jones KP. CNS Drugs. 2011 May;25(5):435-45. doi: 10.2165/11207260-000000000-00000. CNS Drugs. 2011. PMID: 21476614 Review.
Dextromethorphan, when its metabolism is inhibited by the coadministration of quinidine, has been shown to have a positive effect on the symptoms of pseudobulbar affect. ...Dextromethorphan/quinidine 20 mg/10 mg twice daily was generally well tolerated. ...
Dextromethorphan, when its metabolism is inhibited by the coadministration of quinidine, has been shown to have a positive effect on …
3,269 results

Searches related to "dextromethorphan"